Literature DB >> 1732676

Exposure to organic solvents and risk of haematological malignancies.

L Brandt1.   

Abstract

Epidemiological studies indicating that exposure to organic solvents is a risk factor for haematological malignancies are reviewed. Exposure to benzene is a risk factor for ANLL. A preleukaemic phase with pancytopenia is common and may be associated with a normo- or hypercellular marrow with morphological characteristics suggesting MDS. There are indications that other organic solvents than benzene may be leukaemogenic. Certain chromosome aberrations are characteristic in leukaemic cells from solvent exposed ANLL patients. The average latency time from start of occupational exposure until diagnosis is about 10-11 years. There is epidemiological evidence that exposure to organic solvents may also increase the risk of lymphoproliferative malignancies, i.e. ALL, NHL, HD and myeloma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1732676     DOI: 10.1016/0145-2126(92)90103-e

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

1.  Occupation and malignant lymphoma: a population based case control study in Germany.

Authors:  B Mester; A Nieters; E Deeg; G Elsner; N Becker; A Seidler
Journal:  Occup Environ Med       Date:  2006-01       Impact factor: 4.402

2.  Formaldehyde Exposure and Mortality Risks From Acute Myeloid Leukemia and Other Lymphohematopoietic Malignancies in the US National Cancer Institute Cohort Study of Workers in Formaldehyde Industries.

Authors:  Harvey Checkoway; Linda D Dell; Paolo Boffetta; Alexa E Gallagher; Lori Crawford; Peter Sj Lees; Kenneth A Mundt
Journal:  J Occup Environ Med       Date:  2015-07       Impact factor: 2.162

3.  Rapidly progressive toxic leukoencephalomyelopathy with myelodysplastic syndrome: a clinicopathological correlation.

Authors:  Keun-Hwa Jung; Kon Chu; Young A Kim; Beom S Jeon
Journal:  J Clin Neurol       Date:  2007-03-20       Impact factor: 3.077

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.